指南与共识儿科与产科急症消化、代谢与肾脏急症

COVID-19疫情期间土耳其乳腺癌管理国家共识

Turkish national consensus on breast cancer management during temporary state of emergency due to COVID-19 outbreak.
指南 / 共识 · Turk J Surg · 2020-05-06
一句话结论德尔菲共识:在手术条件改善前,对淋巴结阴性、小体积三阴性、HER2阳性及Luminal A样乳腺癌可考虑新辅助全身治疗;HER2阳性和Luminal B样肿瘤新辅助全身治疗后达临床完全缓解者可考虑延长全身治疗。

该共识采用德尔菲法,由51名经验丰富的乳腺外科和肿瘤内科医生进行两轮9级Likert量表电子投票,针对28个不同临床场景形成46条陈述。第一轮37条达成共识(赞同或反对),9条因未达决策阈值进入第二轮。两轮后,14个场景各形成一条推荐,其余14个场景的32条陈述被否决。总体共识为:在手术条件改善前,对淋巴结阴性、小体积三阴性、HER2阳性及Luminal A样肿瘤可考虑新辅助全身治疗;对HER2阳性和Luminal B样肿瘤新辅助全身治疗后达临床完全缓解者可考虑延长全身治疗。

要点

  • 51名乳腺外科和肿瘤内科医生参与两轮德尔菲投票,共对28个场景的46条陈述达成共识。
  • 第一轮37条达成共识(赞同或反对),9条进入第二轮;最终14个场景各形成一条推荐,其余14个场景的32条陈述被否决。
  • 对淋巴结阴性、小体积三阴性、HER2阳性及Luminal A样乳腺癌,共识为在手术条件改善前可考虑新辅助全身治疗。
  • 对HER2阳性和Luminal B样肿瘤新辅助全身治疗后达临床完全缓解者,共识为可考虑延长全身治疗。

适用人群与场景

  • 乳腺癌患者,适用于COVID-19疫情临时紧急状态期间手术条件受限时。

处置流程与药物剂量

  • 对淋巴结阴性、小体积三阴性、HER2阳性及Luminal A样乳腺癌患者,在手术条件改善前可考虑新辅助全身治疗。
  • 对HER2阳性和Luminal B样肿瘤患者,新辅助全身治疗后达临床完全缓解者可考虑延长全身治疗。

研究设计与关键结果

  • 采用德尔菲法,51名经验丰富的乳腺外科和肿瘤内科医生进行两轮9级Likert量表电子投票。
  • 共对28个不同临床场景的46条陈述进行投票;第一轮37条达成共识(赞同或反对),9条未达决策阈值进入第二轮。
  • 两轮后,14个场景各形成一条推荐,其余14个场景的32条陈述被否决。

证据类型、等级与局限

  • 证据类型:专家共识(德尔菲法)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在COVID-19疫情临时紧急状态期间,对淋巴结阴性、小体积三阴性、HER2阳性及Luminal A样乳腺癌患者,可考虑新辅助全身治疗以替代延迟手术。
  • 对HER2阳性和Luminal B样肿瘤患者,新辅助全身治疗后达临床完全缓解者可考虑延长全身治疗。

指南或共识出处

  • Turkish national consensus on breast cancer management during temporary state of emergency due to COVID-19 outbreak(土耳其COVID-19疫情期间乳腺癌管理国家共识),发表于Turk J Surg。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Cancer care is excessively influenced by the COVID-19 outbreak for various reasons. One of the major concerns is the tendency for delayed surgical treatment of breast cancer patients. The outbreak has urged clinicians to find alternative treatments until surgery is deemed to be feasible and safe. Here in this paper, we report the results of a consensus procedure which aimed to provide an expert opinion-led guideline for breast cancer management during the COVID-19 outbreak in Turkey.

MATERIAL AND METHODS: We used the Delphi method with a 9-scale Likert scale on two rounds of voting from 51 experienced surgeons and medical oncologists who had the necessary skills and experience in breast cancer management. Voting was done electronically in which a questionnaire-formatted form was used.

RESULTS: Overall, 46 statements on 28 different case scenarios were voted. In the first round, 37 statements reached a consensus as either endorsement or rejection, nine were put into voting in the second round since they did not reach the necessary decision threshold. At the end of two rounds, for 14 cases scenarios, a statement was endorsed as a recommendation for each. Thirty-two statements for the remaining 14 were rejected.

CONCLUSION: There was a general consensus for administering neoadjuvant systemic therapy in patients with node-negative, small-size triple negative, HER2-positive and luminal A-like tumors until conditions are improved for due surgical treatment. Panelists also reached a consensus to extend the systemic treatment for patients with HER2-positive and luminal B-like tumors who had clinical complete response after neoadjuvant systemic therapy.

来源:Turk J Surg,查看原文。版权归原作者所有。

参考来源

  1. Sezer A, Cicin İ, Karadeniz Çakmak G, et al. Turkish national consensus on breast cancer management during temporary state of emergency due to COVID-19 outbreak. Turk J Surg. 2020. PMID: 33015560. doi:10.5578/turkjsurg.4815

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。